A Search Service for Abbreviation / Long Form

■ Related PubMed/MEDLINE Info.

[Related PubMed/MEDLINE]
Total Number of Papers: 27
[Display Entries]
[Entries Per Page]
 per page
Page Control
Page: of
Abbreviation : anti-PD-1
Long Form : anti-programmed death-1
No. Year Title Co-occurring Abbreviation
2020 Increased thyroid uptake on 18F-FDG PET/CT is associated with the development of permanent hypothyroidism in stage IV melanoma patients treated with anti-PD-1 antibodies. AUC, PET, PTD
2020 Long-Term Outcomes and Responses to Retreatment in Patients With Melanoma Treated With PD-1 Blockade. CR
2020 Nivolumab in Combination with Irinotecan and 5-Fluorouracil (FOLFIRI) for Refractory Advanced Gastroesophageal Cancer. OS, PFS
2020 Retreatment with anti-PD-1 antibody in non-small cell lung cancer patients previously treated with anti-PD-L1 antibody. anti-PD-L1, irAEs, NSCLC
2019 A case of small-cell lung cancer with adrenocorticotropic hormone deficiency induced by nivolumab. ---
2019 AGI-134: a fully synthetic alpha-Gal glycolipid that converts tumors into in situ autologous vaccines, induces anti-tumor immunity and is synergistic with an anti-PD-1 antibody in mouse melanoma models. ADCC, APCs, CDC
2019 Checkpoint Inhibitors. anti-CTLA-4, anti-PD-L1
2019 Dramatic Response to Concurrent Anti-PD-1 Therapy and Radiation in Resistant Tumors with Sarcomatoid Differentiation. ---
2019 Impact of Radiotherapy Concurrent with Anti-PD-1 Therapy on the Lung Tissue of Tumor-Bearing Mice. ---
10  2019 Major histocompatibility complex class II molecule in non-small cell lung cancer diagnosis, prognosis and treatment. APCs, IFN-gamma, MHC class II, NSCLC
11  2019 Paraneoplastic Pemphigus Revealed by Anti-programmed Death-1 Pembrolizumab Therapy for Cutaneous Squamous Cell Carcinoma Complicating Hidradenitis Suppurativa. PNP, SCC
12  2019 Programmed Death-1 or Programmed Death Ligand-1 Blockade in Patients with Platinum-resistant Metastatic Urothelial Cancer: A Systematic Review and Meta-analysis. anti-PD-L1, mUC, RMST
13  2019 Strategies for Recognizing and Managing Immune-Mediated Adverse Events in the Treatment of Hodgkin Lymphoma with Checkpoint Inhibitors. auto-HCT, cHL, HL, IMAEs, PD-1
14  2018 A Network Meta-analysis Comparing the Efficacy and Safety of Anti-PD-1 with Anti-PD-L1 in Non-small Cell Lung Cancer. anti-PD-L1, CIs, HRs, NSCLC, ORs, OS, PFS
15  2018 Activity of pembrolizumab in relapsed/refractory NK/T-cell lymphoma. NKTCL
16  2018 Camrelizumab (SHR-1210) alone or in combination with gemcitabine plus cisplatin for nasopharyngeal carcinoma: results from two single-arm, phase 1 trials. ---
17  2018 Lung cancer, elderly and immune checkpoint inhibitors. anti-PD-L1, NSCLC
18  2018 Mucous Membrane Pemphigoid, Bullous Pemphigoid, and Anti-programmed Death-1/ Programmed Death-Ligand 1: A Case Report of an Elderly Woman With Mucous Membrane Pemphigoid Developing After Pembrolizumab Therapy for Metastatic Melanoma and Review of the Literature. MMP, PD-L1
19  2018 PD-1 Modulates Radiation-Induced Cardiac Toxicity through Cytotoxic T Lymphocytes. CIR, RICT
20  2018 Radiotherapy with the anti-programmed cell death ligand-1 immune checkpoint blocker avelumab: acute toxicities in triple-negative breast cancer. BC, ICIs, irAEs, RT, TNBC
21  2018 Self-associated molecular patterns mediate cancer immune evasion by engaging Siglecs on T cells. NSCLC, SAMPs
22  2018 Systemically Administered Sindbis Virus in Combination with Immune Checkpoint Blockade Induces Curative Anti-tumor Immunity. SV, SV-NYESO1
23  2018 The efficacy and safety of nivolumab, pembrolizumab, and atezolizumab in treatment of advanced non-small cell lung cancer. ALK, anti-PD-L1, EGFR, NSCLC
24  2017 Programmed Death Ligand 1 Expression in Paired Non-Small Cell Lung Cancer Tumor Samples. NSCLC, PD-L1
25  2016 Clinical outcomes of melanoma brain metastases treated with stereotactic radiation and anti-PD-1 therapy. BMs, OS, SRS
26  2016 Management of Adverse Events Following Treatment With Anti-Programmed Death-1 Agents. irAEs
27  2015 Radiotherapy combined with immune checkpoint blockade immunotherapy: Achievements and challenges. anti-CTLA-4, mAbs, RT